Complete 5,000 test results per hour on a proven molecular genomics testing platform with unmatched capacity
It’s time to redefine large-scale COVID-19 testing. For labs ready to scale to support mass testing, LGC, Biosearch Technologies offers an ultra-high-throughput (uHTP) end-point PCR testing system for SARS-CoV-2 detection now submitted to the FDA for Emergency Use Authorization (EUA).
The Biosearch Technologies workflow combines the Nexar™ industrial scale, automated end-point PCR testing platform with our robust, high-quality testing reagent components. UgenTec’s FastFinder software seamlessly integrates with Biosearch Technologies’ instrumentation to provide full traceability of the sample down to individual wells on the Array Tape™ consumable, which allows the user to easily pull up a sample’s status.
See if ultra-high-throughput is right for your lab
The LGC, Biosearch Technologies SARS-CoV-2 ultra-high-throughput End-Point RT-PCR Test
Biosearch Technologies’ SARS-CoV-2 testing workflow can expand testing capacity at 5,000 completed test results per hour with minimal need for additional staff, instrumentation, or lab space. This optimised package of hardware, reagents, consumables and software includes:
The industrial scale Nexar™ (end-point PCR) and Hydrocycler2™ (thermal cycling) platforms.
A dedicated customer service representative who ensures that your supply, hardware and service needs are anticipated and met.